CN102106925A - Medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator - Google Patents
Medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator Download PDFInfo
- Publication number
- CN102106925A CN102106925A CN2009102174740A CN200910217474A CN102106925A CN 102106925 A CN102106925 A CN 102106925A CN 2009102174740 A CN2009102174740 A CN 2009102174740A CN 200910217474 A CN200910217474 A CN 200910217474A CN 102106925 A CN102106925 A CN 102106925A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- polysaccharide
- bacillus bifidus
- regulator
- lycium barbarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 15
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 15
- 241000186000 Bifidobacterium Species 0.000 title abstract description 8
- 230000008685 targeting Effects 0.000 title abstract description 8
- 230000000112 colonic effect Effects 0.000 title abstract description 7
- 240000002624 Mespilus germanica Species 0.000 title abstract 5
- 235000017784 Mespilus germanica Nutrition 0.000 title abstract 5
- 235000000560 Mimusops elengi Nutrition 0.000 title abstract 5
- 235000007837 Vangueria infausta Nutrition 0.000 title abstract 5
- 239000002775 capsule Substances 0.000 claims abstract description 19
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- 229960001631 carbomer Drugs 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 23
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 14
- -1 polypropylene Polymers 0.000 claims description 13
- 210000001072 colon Anatomy 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 12
- 239000004743 Polypropylene Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 229920001155 polypropylene Polymers 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 210000000936 intestine Anatomy 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 2
- 229920001491 Lentinan Polymers 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 229940115286 lentinan Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 12
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 11
- 235000018291 probiotics Nutrition 0.000 abstract description 11
- 208000036649 Dysbacteriosis Diseases 0.000 abstract description 9
- 208000027244 Dysbiosis Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 9
- 230000007140 dysbiosis Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 7
- 206010012735 Diarrhoea Diseases 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229960003444 immunosuppressant agent Drugs 0.000 abstract description 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000004925 Acrylic resin Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 235000013406 prebiotics Nutrition 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 5
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 3
- 201000007637 bowel dysfunction Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator. The medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator is a Chinese medicinal colonic targeting microecological regulator prepared by putting the mixture of medlar polysaccharide extract, bifidobacterium and carbomer into polyacrylic resin capsules. The medlar polysaccharides are snybiotics, the bifidobacterium is probiotics, the snybiotics can enforce fix planting, growth and colonic targeting formulation of the probiotics, avoid the damage to the probiotics in the stomach and the small intestines and enhance the in vivo growth of the bifidobacterium which is predominant bacteria of human body to achieve the aim of regulate dysbacteriosis of the intestinal tract and regain the microecological balance of human body; the regulator can used for treating intestinal catarrh, diarrhea and constipation due to the dysbacteriosis caused by antibiotics, hormones, immunosuppressants, cytotoxicity medicaments and the like and side effects of the medicaments and simultaneously improve the health state of human body and protect human health.
Description
Technical field: the present invention relates to the segmented intestine targeted microecologic regulator of a kind of lycium barbarum polysaccharide bacillus bifidus symphysis unit, belong to Chinese medicine preparation.
Background technology: dysbacteriosis, serious threat human life with healthy, at present, the microecologic regulator of treatment dysbacteriosis both at home and abroad mainly is probiotics preparation (stomach dissolution type), the colitis that causes with this type of preparation for treating dysbacteriosis, constipation, during diarrhoea, because arriving stomach, preparation promptly discharges medicine, make viable bacteria be subjected to gastric acid, influences such as various enzymes and being damaged, the viable bacteria that can not guarantee sufficient amount enters colon, and the human body dysbacteriosis mainly refers to colonic flora disequilibrium, therefore, viable bacteria class microecologic regulator is answered the targeting colon, could guarantee that viable bacteria enters field planting smoothly, growth site is recovered the intestinal microbial population balance, reaches the purpose of the diseases such as bowel dysfunction that the treatment alteration of intestinal flora causes.
Summary of the invention: the shortcoming that the objective of the invention is to overcome common stomach dissolution type microecologic regulator, provide a kind of lycium barbarum polysaccharide bacillus bifidus symphysis unit segmented intestine targeted microecologic regulator, it is obvious to the bowel dysfunction effect that the treatment alteration of intestinal flora causes, it can make medicine in colonic targeting, field planting, growth, dissolving release.The object of the present invention is achieved like this, and it is prebiotics with the lycium barbarum polysaccharide, and bacillus bifidus is a probiotic bacteria, and the colon adhesion material is a carbomer, and colon colloidal sol capsule material is the polypropylene acid resin.Calculate by a capsules: Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide 0.1-0.2g, bacillus bifidus 0.1g-0.2g, colon adhesion material carbomer 0.05g, colon colloidal sol capsule material is the polypropylene acid resin.Its preparation method is that in the colon colloidal sol capsule of packing into, packing gets final product with Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide, bacillus bifidus, carbomer mixing in proportion.Lycium barbarum polysaccharide has immunoregulation effect in this invention; can obviously improve cytophagous phagocytic function; improve the lymphocytic multiplication capacity of T; increase serum IgG content; strengthen complement activity, resisting fatigue, defying age, blood fat reducing, foster the bifidobacterium growth effect, ischemic brain injury is had significant protective effect; can improve the brain function state, also have antibacterial and effect such as hepatoprotective.Bacillus bifidus can form a biological barrier on the intestinal mucosa surface, stops field planting and the invasion of pathogenic bacterium, is used for the bowel dysfunction that alteration of intestinal flora causes, as acute and chronic diarrhoea, the treatment of constipation, enteritis etc. improves body immunity, simultaneously prevention and the treatment of infecting is had assosting effect.The present invention is with Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide, with bacillus bifidus and carbomer mixing, the Chinese medicine microecologic regulator of packing into and making in the polypropylene acid resin capsule, it has the effect of keeping and regulate the human body microecological balance, it promotes probiotic bacteria field planting, growth with prebiotics, segmented intestine targeted dosage form is avoided the destruction of probiotic bacteria at stomach and small intestinal, for its treatment alteration of intestinal flora provides novel form, treatment of diseases such as colitis, constipation, diarrhoea and China's natural resources of Chinese medicinal materials development and use had positive meaning.Treat dysbacteriosis with microecologic regulator, can treat and use the dysbacteriosis that antibiotic, hormone, immunosuppressant, cytotoxic drug etc. are caused, the health status that simultaneously also can promote human body, symphysis unit preparation is as microecologic regulator of new generation, with probiotic bacteria and prebiotics use in conjunction, bring into play the function of probiotic bacteria and prebiotics simultaneously, prebiotics promotes probiotics field planting in intestinal, growth, breeding, make probiotic bacteria and prebiotics synergism, resist the dysbacteriosis disease jointly, safeguard the microecological balance of body.This regulator is through alteration of intestinal flora patient 105 people's clinical practices, and treatment diarrhoea effective percentage reaches 81%.
The segmented intestine targeted microecologic regulator pharmacodynamic experiment data of lycium barbarum polysaccharide and bacillus bifidus symphysis unit:
The blank group: prepare above-mentioned 5 kinds of intestinal broth bouillons, aseptic take mice cecal content homogenizing after, respectively the inoculation, cultivate respectively by condition of culture.
Lycium barbarum polysaccharide group: add lycium barbarum polysaccharide solution in the broth bouillon of five kinds of normal intestinal floras respectively,, cultivate respectively by condition of culture by blank group operation inoculation.
Cultivate the accelerating all of five kinds of floras of back lycium barbarum polysaccharide group, and have significant difference more than the blank group.Wherein remarkable with bacillus bifidus, lactobacillus, illustrate that lycium barbarum polysaccharide has the effect that bacillus bifidus promotes its propagation of fostering.
The specific embodiment:
Embodiment 1:
Calculate by a capsules: get Lycium barbarum polysaccharide extract 0.2g, bacillus bifidus 0.1g, colon adhesion material carbomer 0.05g.
Embodiment 2:
Calculate by a capsules: get Lycium barbarum polysaccharide extract 0.1g, bacillus bifidus 0.2g, carbomer 0.05g.
Embodiment 3:
Lycium barbarum polysaccharide extract is other Chinese medicinal plant polysaccharide or oligosaccharide, as one of them of pachyman, ginseng polysaccharide, ganoderan, lentinan, stachyose etc.
Its preparation method is that in the polypropylene acid resin capsule of packing into, packing gets final product with the Lycium barbarum polysaccharide extract of above-mentioned weight, other Chinese medicinal plant polysaccharide or oligosaccharide and bacillus bifidus, carbomer mixing in proportion.
Also can be with bacillus bifidus and carbomer mixing, in the polypropylene acid resin capsule of packing into, or bacillus bifidus to be packed in the polypropylene acid resin capsule, packing gets final product.
Polypropylene acid resin capsule is that Chao Zhou city strong basis pharmaceutical factory produces, and is mainly used in colon targeting drug administration, and this capsule dissolves release according to pH principle insoluble release medicine of separating under stomach and small intestinal pH value condition under colon pH value condition.
This medicine ingredient is analyzed and incompatibility:
This preparation is the compound preparation of Chinese medicine Lycium barbarum polysaccharide extract and bacillus bifidus, is index with the prebiotics polysaccharide, measures the preparation polyoses content with the phenol sulfuric acid process, detects bifidobacteria viable bacteria quantity simultaneously.
Can weaken its curative effect when antacid, antimicrobial drug and this preparation share, should separately take.
Consumption and usage: 2/day, the heavy 0.35g of every capsules.
Claims (5)
1. the segmented intestine targeted microecologic regulator of lycium barbarum polysaccharide bacillus bifidus symphysis unit, it is characterized in that: calculate by a capsules: Lycium barbarum polysaccharide extract 0.1-0.2g, bacillus bifidus 0.1-0.2g, colon adhesion material carbomer 0.05g, colon colloidal sol capsule material is the polypropylene acid resin.
2. the segmented intestine targeted microecologic regulator of the described lycium barbarum polysaccharide bacillus bifidus of claim 1 symphysis unit, it is characterized in that: Lycium barbarum polysaccharide extract is other Chinese medicinal plant polysaccharide or oligosaccharide, as one of them of pachyman, ginseng polysaccharide, ganoderan, lentinan, stachyose etc.
3. claim 1 or 2 described preparation methoies is characterized in that: with the Lycium barbarum polysaccharide extract of above-mentioned weight or Chinese medicinal plant polysaccharide or oligosaccharide and bacillus bifidus, carbomer mixing in proportion, in the polypropylene acid resin capsule of packing into, packing gets final product.
4. the described preparation method of claim 3 is characterized in that: also can be with bacillus bifidus and carbomer mixing, and in the polypropylene acid resin capsule of packing into, packing gets final product.
5. the described preparation method of claim 3 is characterized in that: bacillus bifidus is packed in the polypropylene acid resin capsule, and packing gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910217474A CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910217474A CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102106925A true CN102106925A (en) | 2011-06-29 |
| CN102106925B CN102106925B (en) | 2012-09-19 |
Family
ID=44171281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910217474A Expired - Fee Related CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102106925B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105996050A (en) * | 2016-05-12 | 2016-10-12 | 李�浩 | Lactic acid bacterium preparation for improving gastrointestinal function and preparation method |
| CN106265876A (en) * | 2016-10-14 | 2017-01-04 | 青岛自然珍萃生物科技有限公司 | A kind of probiotic composition and the application in alleviation or treatment constipation thereof |
| WO2018086550A1 (en) * | 2016-11-11 | 2018-05-17 | 南京希尔寿生物科技有限公司 | Biological active component colon-targeted composition and application thereof |
| CN113812622A (en) * | 2021-09-10 | 2021-12-21 | 盛尚杞美(宁夏)生物科技开发有限公司 | Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof |
| CN114057904A (en) * | 2021-11-03 | 2022-02-18 | 沈阳农业大学 | Sulfhydryl codonopsis pilosula polysaccharide and application thereof in preparation of colon-targeted probiotic microcapsules |
| CN114698848A (en) * | 2022-04-11 | 2022-07-05 | 深圳海创生物科技有限公司 | Active polysaccharide and probiotic composition and application thereof in preparation of food or medicine with constipation relieving effect |
| CN116603069A (en) * | 2023-04-10 | 2023-08-18 | 南方科技大学 | Microorganism targeting implantation system and method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727465A (en) * | 2004-07-28 | 2006-02-01 | 卢晓蕊 | Wine tea fermented from tea, medlar and Chinese dates |
-
2009
- 2009-12-28 CN CN200910217474A patent/CN102106925B/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105996050A (en) * | 2016-05-12 | 2016-10-12 | 李�浩 | Lactic acid bacterium preparation for improving gastrointestinal function and preparation method |
| CN106265876A (en) * | 2016-10-14 | 2017-01-04 | 青岛自然珍萃生物科技有限公司 | A kind of probiotic composition and the application in alleviation or treatment constipation thereof |
| WO2018086550A1 (en) * | 2016-11-11 | 2018-05-17 | 南京希尔寿生物科技有限公司 | Biological active component colon-targeted composition and application thereof |
| US11337926B2 (en) | 2016-11-11 | 2022-05-24 | Nanjing Healsoul Life Science And Technology Co., Ltd. | Colon-targeted composition of biological active component and application thereof |
| CN113812622A (en) * | 2021-09-10 | 2021-12-21 | 盛尚杞美(宁夏)生物科技开发有限公司 | Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof |
| CN114057904A (en) * | 2021-11-03 | 2022-02-18 | 沈阳农业大学 | Sulfhydryl codonopsis pilosula polysaccharide and application thereof in preparation of colon-targeted probiotic microcapsules |
| CN114698848A (en) * | 2022-04-11 | 2022-07-05 | 深圳海创生物科技有限公司 | Active polysaccharide and probiotic composition and application thereof in preparation of food or medicine with constipation relieving effect |
| CN114698848B (en) * | 2022-04-11 | 2024-04-09 | 深圳海创生物科技有限公司 | Active polysaccharide and probiotic composition and application thereof in preparation of health-care food or medicine with constipation relieving effect |
| CN116603069A (en) * | 2023-04-10 | 2023-08-18 | 南方科技大学 | Microorganism targeting implantation system and method |
| CN116603069B (en) * | 2023-04-10 | 2024-03-12 | 南方科技大学 | Microorganism targeting implantation system and method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102106925B (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102106925B (en) | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator | |
| CN108671135A (en) | A kind of Traditional Chinese medicine probiotic compound of conditioning insomnia and depression | |
| CN1843385A (en) | Enteral microecological formulation and its preparation process | |
| CN118593558B9 (en) | Animal bifidobacterium and radish seed composition with synergistic effect of preventing and treating functional constipation | |
| US20210268051A1 (en) | Methods of using smectite compositions for treating clostridium difficile associated diseases and symptoms | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| CN112370470A (en) | Microecological preparation for reconstructing intestinal microecology | |
| CN101336938B (en) | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease | |
| CN107998152A (en) | A kind of probiotics tablets of colon release | |
| CN104013649A (en) | Bacillus licheniformis symbiotic composition and preparations thereof | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN106074975A (en) | A kind of compositions and the application in preparation improves the product of function of intestinal canal thereof | |
| CN108641991A (en) | A kind of composite viable bacteria preparation and preparation method and its application | |
| ITMI950378A1 (en) | ASSOCIATIONS OF LACTIC FERMENTS AND SACCAROMYCE LYSATES, THEIR THERAPEUTIC USE AND COMPOSITIONS THAT CONTAIN THEM | |
| CN101485687B (en) | Medicament for treating gastrointestinal tract disease using biological viable bacteria | |
| CN111528486A (en) | Composition containing lactoferrin | |
| CN113750113B (en) | Composition of probiotics and prebiotics and application thereof | |
| CN118599741B (en) | Animal bifidobacterium and hemp seed composition with synergistic effect of preventing and treating functional constipation | |
| CN109549957A (en) | The compound probiotic of energy bidirectional modulation constipation | |
| CN107279234A (en) | The biscuit of healthy intestinal health | |
| Wu et al. | The Ecological Regulating Effect of Exopolysaccharides Produced by Bifidobacterium on Intestinal Microecological Imbalance. | |
| US20090110663A1 (en) | Method for treatment of bowel disorders | |
| CN116966206A (en) | Use of Lactobacillus fermentum for the preparation of products for the prevention and/or treatment of purgative colon | |
| CN115998802A (en) | Fermentation method of chicory and raspberry compound | |
| CN106511371A (en) | Compound prebiotic and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 Termination date: 20161228 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |